Dr. Samuel G. Deem, DO
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- West Virginia School of Osteopathic Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 579
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: West Virginia School of Osteopathic Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
WV license 2176
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Charleston Area Medical Center Charleston, WV
- Camc Greenbrier Valley Medical Center, Inc Ronceverte, WV
- Boone Memorial Hospital Madison, WV
- Logan Regional Medical Center Logan, WV
- Camc Charleston Surgical Hospital Charleston, WV
Medical groups
- Charleston Area Medical Center Inc (985 clinicians)
- Camc Greenbrier Valley Medical Center Inc (84 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 579
- Services billed
- 1,257
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 235 | 204 |
| Established patient office or other outpatient visit, 30-39 minutes | 217 | 163 |
| Diagnostic exam of bladder and urethra using an endoscope | 131 | 88 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 100 | 94 |
| New patient office or other outpatient visit, 30-44 minutes | 46 | 46 |
| New patient office or other outpatient visit, 45-59 minutes | 45 | 45 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 39 | 22 |
| Ultrasound scan of pelvic region through rectum | 33 | 29 |
| Established patient office or other outpatient visit, 10-19 minutes | 32 | 32 |
| Telephone medical discussion with physician, 11-20 minutes | 25 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Charleston, WV | 443 |
| Cephalexin Other prescribers in Charleston, WV | 191 |
| Finasteride Other prescribers in Charleston, WV | 120 |
| Levofloxacin Other prescribers in Charleston, WV | 84 |
| Oxybutynin Chloride Er (oxybutynin chloride) Other prescribers in Charleston, WV | 77 |
| Myrbetriq (mirabegron) Other prescribers in Charleston, WV | 56 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Charleston, WV | 51 |
| Silodosin Other prescribers in Charleston, WV | 47 |
| Xtandi (enzalutamide) | 46 |
| Estradiol Other prescribers in Charleston, WV | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 24 payments worth $935 in total to this clinician.
| Intuitive Surgical, Inc. | $184 |
|---|---|
| Boston Scientific Corporation | $165 |
| Janssen Scientific Affairs, LLC | $150 |
| Olympus America Inc. | $118 |
| Astellas Pharma US Inc | $85.43 |
| Sumitomo Pharma America, Inc. | $80.79 |
| Pfizer Inc. | $43.97 |
| Novartis Pharmaceuticals Corporation | $26.66 |
| Food and Beverage | $935 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $121,239 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants wi…
Merck Sharp & Dohme LLC - A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Inelig…
Merck Sharp & Dohme LLC - A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle…
Merck Sharp & Dohme LLC - Study name not reported
Organon Llc - A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy
Janssen Research & Development, LLC - Study name not reported
Organon Llc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.